Phoqus Pharmaceuticals Company

Phoqus group is a specialty pharmaceutical company, engages in the development and commercialization of drugs that meet unmet medical needs using the electrostatic deposition technology. Its primary product Chronocort is a Phase II clinical trial product used for the treatment of congenital adrenal hyperplasia and Addison's disease. The company’s drug delivery platform, Qtrol, which is derived from electrostatic deposition, enables solid oral dosage forms, such as tablets to be coated in a controlled and precise manner that could then be used to modify the way that a drug is released into the body.
Technology: Research
Industry: Personalized Medicine
Headquarters: West Malling, Kent, United Kingdom
Founded Date: 1998
Employees Number: Undisclosed
Funding Status: IPO

Visit Website
phoqus@dundee.ac.uk
@phoqus_fp7
Register and Claim Ownership